BetaPharma Drug Discovery
BetaPharma Drug Discovery Accelerating Drug Discovery

From operational standpoint, Betapharma has chosen a very lean internal structure, retaining only the strategic skills and activities in-house, while relying on various partnerships and networking for
accessing the most suitable options on a timely.

From scientific standpoint, Betapharma is selecting drug targets with strong clinical validation in areas where we have the potential to generate either first-in-class molecules or compounds that are highly differentiated from existing treatments.

From business standpoint, Betapharma has chosen a novel combination of R&D centers in USA and China:

* USA headquarter responsible for targets and leads identification, regulatory fairs include IND application, international clinical trial and marketing

* Chinese R&D centers responsible for optimization, preclinical and clinical studies in China and Chinese marketing

From marketing standpoint, Betapharma complete by Chinese marketing by partnership with Chinese partners’ Betapharma R&D centers. International marketing complete by out-licensing or partnership with big pharmaceutical or biotech companies from USA, or European or Japan.

EGFR Inhibitor Program Is Now Our Highest Priority

Given the success we have achieved in the EGFR inhibitor program for NSCLC, one of the most common and deadly forms of cancer, this program is now our highest priority. There is a growing body of preclinical and clinical evidence suggesting Betapharma’ EGFR inhibitor program, Icotinib, has following advantage: